Abstracts tagged "immunology"

Abstract Number: 0698 • ACR Convergence 2021
Flow Cytometry and Sorting of Single Antibody Secreting Cells from Frozen Muscle Tissue
Andrew Zlobin, Peter Pytel and Vladimir Liarski, University of Chicago, Chicago, IL
Background/Purpose: Idiopathic inflammatory myopathies (IIM) – dermatomyositis (DM), polymyositis, and inclusion body myositis - are poorly understood autoimmune muscle disorders. Isolation of relevant immune cell…
Abstract Number: 1512 • ACR Convergence 2021
Epigenetic and Transcriptional Programs of CD4+ T Cell Anergy
Philip Titcombe, Milagros Silva Morales and Daniel Mueller, University of Minnesota, Minneapolis, MN
Background/Purpose: T cell tolerance is essential for preventing autoimmune diseases and resolving inflammation. To maintain tolerance, CD4+ T cells recognizing self-antigens in the periphery can…
Abstract Number: 0025 • ACR Convergence 2021
The Modulatory Capacity of Galectin-3 on the Programmed Death-1 Signaling Axis in Rheumatoid Arthritis
Kathrine Pedersen¹, Morten Aagaard Nielsen², Malene Hvid¹, Bent Deleuran¹ and Stinne Greisen¹, ¹Aarhus University, Aarhus, Denmark, ²Aarhus University / Aarhus University Hopital, Aarhus, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation of the synovium. Despite a variety of treatments, 30-40% of RA patients fail…
Abstract Number: 0876 • ACR Convergence 2021
Antibody Response in Patients with Systemic Lupus Erythematosus After a Two-dose Regimen with SARS-CoV-2 Vaccines (Preliminary Results)
Emilie Stavnsbjerg Larsen¹, Anna Christine Nilsson², Ulrik Stenz Justesen¹, Anne Voss³ and Isik Somuncu Johansen⁴, ¹Odense University Hospital, Odense C, Denmark, ²Odense Universitets Hospital, Odense C, Denmark, ³Department of Rheumatology, Odense University Hospital, Odense C, Denmark, ⁴Odense University Hospital, Odense, Denmark
Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) often receive immunosuppressive treatment for many years, resulting in higher risk of infections, including COVID-19, and infections may…
Abstract Number: 1528 • ACR Convergence 2021
Clinical Consequences of Hepatitis B Core Antibody Positivity After IVIG Administration
William West¹, Therese Posas-Mendoza², Jerald Zakem³, William Davis¹ and Robert Quinet⁴, ¹Ochsner Medical Center, New Orleans, LA, ²Ochsner Clinic Foundation, New Orleans, LA, ³Ochsner Health Systems, Metairie, LA, ⁴Ochsner Health, River Ridge, LA
Background/Purpose: Intravenous immunoglobulin (IVIG) is a blood product created by pooling of donor plasma that is used for a wide range of indications. IVIG is…
Abstract Number: 0046 • ACR Convergence 2021
Psoriatic Arthritis Skin Is Transcriptionally Different to Psoriasis Skin and Enriched in Immunoglobulin Transcripts
Hanna Johnsson¹, John Cole¹, Stefan Siebert¹, Iain McInnes² and Gerard Graham¹, ¹University of Glasgow, Glasgow, United Kingdom, ²University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom
Background/Purpose: Up to 30% of patients with psoriasis develop psoriatic arthritis (PsA). The traditional assumption is that the skin disease is the same in both…
Abstract Number: 0961 • ACR Convergence 2021
Proteomic Profiling of MIS-C Patients Reveals Heterogeneity Relating to Interferon Gamma Dysregulation and Vascular Endothelial Dysfunction
Caroline Diorio¹, Rawan Shraim¹, Laura Vella¹, Josephine Giles², Amy Baxter², Derek Oldridge², Scott Canna¹, Sarah Henrickson¹, Kevin Mcnerney¹, Frances Balamuth¹, Chakkapong Burudpakdee¹, Jessica Lee¹, Tomas Leng¹, Alvin Farrell¹, Michele Lambert¹, Kathleen Sullivan¹, John Wherry³, David Teachey¹, Hamid Bassiri¹ and Edward Behrens¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³UPenn, Philadelphia, PA
Background/Purpose: Multi-system Inflammatory Syndrome in Children (MIS-C) is a major complication of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic in pediatric patients. Children…
Abstract Number: 1546 • ACR Convergence 2021
Immune Responses to COVID-19 Vaccines in Patients Using Immunosuppressive Medication for Inflammatory Arthritis – An Observational Study of 1500 Patients
Ingrid Jyssum¹, Anne Therese Tveter¹, Fridtjof Lund-Johansen², Ludvig Munthe², Sella Provan¹, Kristin Jørgensen³, Gunnveig Grødeland², Grete Kro², David Warren², Joseph Sexton¹, Tore Kvien¹, Siri Mjaaland⁴, Espen Haavardsholm¹, John Torgils Vaage², Silje Watterdal Syversen¹ and Guro Goll¹, ¹Diakonhjemmet Hospital, OSLO, Norway, ²Oslo University Hospital, Oslo, Norway, ³Akershus University Hospital, Lørenskog, Norway, ⁴Norwegian Institute of Public Health, Oslo, Norway
Background/Purpose: To assess the strength and duration of the immunological response to COVID-19 vaccines in patients treated with immunosuppressive medication for inflammatory arthritis.Methods: Adult patients…
Abstract Number: 0056 • ACR Convergence 2021
Peripheral Blood Immune Cell Profiling in Psoriatic Arthritis: Comparison of Patients with Healthy Controls
Lihi Eder¹, Darshini Ganatra² and Vinod Chandran³, ¹University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Heterogeneity in immune cell populations among patients with psoriatic arthritis (PsA) may determine disease expression and treatment response. The objective of this study was…
Abstract Number: 0968 • ACR Convergence 2021
Granzyme K+ CD8 T Cells Form the Core Population of Inflamed Human Tissue-associated CD8 T Cells
Anna Helena Jonsson¹, Fan Zhang², Emma Gomez-Rivas¹, Gerald Watts¹, Garett Dunlap³, Heather Faust¹, Karishma Rupani¹, Joseph Mears¹, Deepak Rao¹, Runci Wang⁴, Gregory Keras¹, Nida Meednu⁵, Jonathan Coblyn¹, Elena Massarotti¹, Derrick Todd¹, Andrew McDavid⁶, Jennifer Anolik⁵, Accelerating Medicines Partnership AMP: RA/SLE Network⁷, Kevin Wei¹, Soumya Raychaudhuri¹ and Michael Brenner⁸, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Harvard University, Somerville, MA, ⁴Brigham and Women’s Hospital, Boston, MA, ⁵University of Rochester Medical center, Rochester, NY, ⁶University of Rochester, Rochester, NY, ⁷NIH/FNIH, Bethesda, MD, ⁸Brigham and Women's Hospital, Harvard Medical School, Newton, MA
Background/Purpose: T cell-derived pro-inflammatory cytokines are a major driver of rheumatoid arthritis (RA) pathogenesis. While CD4 T cells have traditionally been assumed to be the…
Abstract Number: 1689 • ACR Convergence 2021
Safety, Tolerability, Pharmacokinetics, Receptor Occupancy, and Suppression of T-cell-Dependent Antibody Response in a Phase 1 Study with KPL-404, an anti-CD40 Monoclonal Antibody
Manoj Samant¹, Alistair Wheeler², Guang-Liang Jiang¹, Moses Njenga¹, Madeline Spiers¹, Arian Pano¹ and John F Paolini¹, ¹Kiniksa Pharmaceuticals Corp., Lexington, MA, ²Kiniksa Pharmaceuticals, Ltd., Hamilton, Bermuda
Background/Purpose: T-cell priming and T-cell-dependent B-cell responses require an intact cluster of differentiation (CD)40/CD40L pathway. CD40 is expressed on the surface of B-cells, dendritic cells,…
Abstract Number: 0059 • ACR Convergence 2021
Deep Immune Cell Profiling of Tissue Microenvironment Using Imaging Mass Cytometry in Psoriatic Disease
Lihi Eder¹, Stephane Caucheteux¹, Somi Afiuni², Adriana Krizova¹, James Limacher¹, Hartland Jackson¹ and Vincent Piguet¹, ¹University of Toronto, Toronto, ON, Canada, ²Lunenfeld Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada
Background/Purpose: Cross talk between different cell types, such as T cell subsets and other immune cell populations, is important in psoriatic disease. Imaging Mass Cytometry…
Abstract Number: 0993 • ACR Convergence 2021
The Mechanistic Basis of anti-CD6 as a Novel Form for the Treatment of Autoimmune Diseases and Cancer
Mikel Gurrea-Rubio¹, Jeffrey Ruth¹, Qi Wu¹, Eliza Pei-Suen Tsou¹, Phillip Campbell¹, Peggy Randon¹, M.Asif Amin¹, Nora Singer², Feng Lin³ and David Fox¹, ¹University of Michigan, Ann Arbor, MI, ²The MetroHealth System, Cleveland, OH, ³Cleveland Clinic, Cleveland, OH
Background/Purpose: The use of Immune Checkpoint Inhibitors (ICIs) is limited by the induction of immune-related adverse events. CD6 is expressed by most T lymphocytes and…
Abstract Number: 1772 • ACR Convergence 2021
Autologous EBV-specific Cytotoxic T Cells in Systemic Lupus Erythematosus: An Innovative Phase I/IIa Clinical Trial
Antoine Enfrein¹, Beatrice Clemenceau², Soraya Saiagh³, Céline Bressollette⁴, Zahir Amoura⁵, Henri Vie² and Mohamed Hamidou¹, ¹Médecine interne, CHU de Nantes, Nantes, France, ²Inserm U1232, Université de Nantes, Nantes, France, ³Unité de Thérapie Cellulaire et Génique, CHU de Nantes, Nantes, France, ⁴Laboratoire de Virologie, CHU de Nantes, Nantes, France, ⁵Médecine interne, Hôpital Pitié Salpêtrière, AP-HP, Paris, France
Background/Purpose: Epstein-Barr Virus (EBV) has been suggested as a potential environmental factor in systemic lupus erythematosus (SLE) onset and disease activity. Here, we report the…
Abstract Number: 0113 • ACR Convergence 2021
Reactogenicity of the SARS-CoV-2 Vaccines Associates with Immunogenicity in Patients with Autoimmune and Inflammatory Disease
Monica Yang¹, Kimberly E. Taylor¹, Diana Paez¹, Alex Carividi¹, Emanuel Demissie¹, Niti Pawar¹, Alia A. El-Qunni,², Lily E. McMorrow², Rebecca E. Schriefer², Katherine Huang², Baylee Kinnett², Wooseob Kim², Ali H Ellebedy², Matthew Ciorba², Michael Paley³, Parakkal Deepak², Alfred Kim², Patricia Katz¹, Mehrdad Matloubian¹, Mary Nakamura⁴ and Lianne Gensler⁵, ¹University of California San Francisco, San Francisco, CA, ²Washington University School of Medicine, St. Louis, MO, ³Washington University in St. Louis, Olivette, MO, ⁴UCSF/SFVAHCS, San Francisco, CA, ⁵Department of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Little is known about the reactogenicity and related SARS-CoV-2 vaccine response in patients with chronic inflammatory disease (CID). While researchers have hypothesized increased symptomatology…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].